• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Deciphera Pharmaceuticals, LLC - Product Pipeline Review - Q4 2010 Product Image

Deciphera Pharmaceuticals, LLC - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 31 pages
  • GlobalData

Deciphera Pharmaceuticals, LLC – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Deciphera Pharmaceuticals, LLC - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Deciphera Pharmaceuticals, LLC - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Deciphera Pharmaceuticals, LLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Deciphera Pharmaceuticals, LLC Snapshot
Deciphera Pharmaceuticals, LLC Overview
Key Information
Key Facts
Deciphera Pharmaceuticals, LLC – Research and Development Overview
Key Therapeutic Areas
Deciphera Pharmaceuticals, LLC – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Deciphera Pharmaceuticals, LLC – Pipeline Products Glance
Deciphera Pharmaceuticals, LLC Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Deciphera Pharmaceuticals, LLC–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Deciphera Pharmaceuticals, LLC – Drug Profiles
DCC-2036
Product Description
Mechanism of Action
R&D Progress
DCC-2157
Product Description
Mechanism of Action
R&D Progress
DP-2514
Product Description
Mechanism of Action
R&D Progress
DP-3346
Product Description
Mechanism of Action
R&D Progress
DP-3407
Product Description
Mechanism of Action
R&D Progress
DP-3429
Product Description
Mechanism of Action
R&D Progress
DP-3590
Product Description
Mechanism of Action
R&D Progress
Deciphera Pharmaceuticals, LLC – Pipeline Analysis
Deciphera Pharmaceuticals, LLC – Pipeline Products by Therapeutic Class
Deciphera Pharmaceuticals, LLC Pipeline Products By Target
Deciphera Pharmaceuticals, LLC – Pipeline Products by Route of Administration
Deciphera Pharmaceuticals, LLC – Locations And Subsidiaries
Head Office
Recent Developments
Mar 25, 2009: Deciphera Pharmaceuticals Announces Initation Of DCC-2036 Phase I Clinical Trial In Refractory CML and ALL
Mar 25, 2009: Deciphera Pharmaceuticals Announces Initation Of DCC-2036 Phase I Clinical Trial In Refractory CML and ALL
Financial Deals Landscape
Deciphera Pharmaceuticals, LLC, Deals Summary, 2004 to 2010
Deciphera Pharmaceuticals, LLC Detailed Deal Summary
Eli Lilly Enters Into Agreement With Deciphera Pharmaceuticals
deCODE Extends Research Agreement With Deciphera Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS